mRNA Cancer Vaccines and Therapeutics Market Report 2024

The mRNA cancer vaccines and therapeutics market size has grown rapidly in recent years. It will grow from $52.85 billion in 2023 to $61.52 billion in 2024 at a compound annual growth rate (CAGR) of 16.4%. The growth observed in the historic period can be attributed to several factors, including changing lifestyles impacting healthcare needs, increased funding and investment support in medical research and development, favorable regulatory environments facilitating innovation, the presence of well-established healthcare infrastructures supporting treatment advancements, and the continuous development of new therapeutic pipelines.

The mRNA cancer vaccines and therapeutics market size is expected to see rapid growth in the next few years. It will grow to $113.41 billion in 2028 at a compound annual growth rate (CAGR) of 16.5%. In the forecast period, growth can be attributed to promising results from clinical trials, increasing awareness and acceptance of mRNA technology in cancer treatment, significant unmet medical needs, potential for enhanced patient outcomes, and the prospect of off-the-shelf availability of treatments. Major trends anticipated in this period include expanding into new therapeutic areas, leveraging personalized medicine approaches tailored to individual patient profiles, advancements in mRNA delivery systems to optimize effectiveness and safety, development of multivalent mRNA vaccines targeting multiple antigens, and the integration of artificial intelligence and machine learning in optimizing mRNA design for enhanced therapeutic efficacy.

The increasing prevalence of cancer is set to drive growth in the mRNA cancer vaccine and therapeutic market in the coming years. Cancer encompasses a diverse group of diseases characterized by abnormal cell growth and invasion into healthy tissues, influenced by factors such as sedentary lifestyles, poor dietary habits, and exposure to environmental toxins. mRNA cancer vaccines and therapeutics play a crucial role in cancer treatment by offering personalized and targeted therapies that enhance the immune system's ability to identify and combat cancer cells, thereby improving treatment effectiveness and patient outcomes. For example, data published by the American Cancer Society in January 2023 reported an estimated increase in new cancer cases in the United States, rising from approximately 1,918,030 cases in 2022 to 1,958,310 cases in 2023. Breast cancer remains a significant concern, with reported cases increasing from 287,850 in 2022 to 297,790 in 2023. This underscores the driving force behind the growth of the mRNA cancer vaccine and therapeutics market.

Leading companies in the mRNA cancer vaccine and therapeutics market are focused on developing innovative treatments, particularly mRNA cancer vaccines, aimed at enhancing efficacy and addressing the rising demand for effective cancer therapies. mRNA cancer vaccines utilize messenger RNA to instruct cells to produce specific antigens, stimulating the immune system to recognize and target cancer cells. For instance, in May 2024, WestGene Biopharma, a China-based biotechnology company, received FDA approval for its investigational new drug application of WGc-043, an mRNA therapeutic cancer vaccine. This development represents a significant advancement in treating advanced EB virus-related cancers, associated with various malignancies such as nasopharyngeal carcinoma, NK T-cell lymphoma, and others, along with autoimmune diseases such as multiple sclerosis and lupus.

In September 2021, Sanofi Inc., a France-based pharmaceutical company, completed its acquisition of Translate Bio Inc. for $3.2 billion. This acquisition positions Sanofi to accelerate its efforts in mRNA technology, bolstering its capabilities in developing innovative vaccines and therapies. Translate Bio Inc., based in the US, specializes in mRNA therapeutics and has significantly contributed to advancing mRNA-based medicine development.

Major companies operating in the mRNA cancer vaccines and therapeutics market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis SA, Sanofi AG, AstraZeneca Plc, GlaxoSmithKline Plc, Hoffmann-La Roche AG, Eli Lilly and Company, Moderna Therapeutics Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Catalent Inc., Sarepta Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Genentech Inc., Immatics Biotechnologies GmbH, CureVac N.V, Anima Biotech, Argos Therapeutics Inc.

North America was the largest region in the mRNA cancer vaccination and therapeutics market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mRNA cancer vaccines and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mRNA cancer vaccines and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

mRNA cancer vaccines and therapeutics utilize messenger RNA (mRNA) to stimulate the immune system in fighting cancer cells. This approach delivers instructions to cells to produce therapeutic proteins or enzymes, aiding in priming the immune system to identify and target cancer cells expressing specific antigens.

The main types of mRNA cancer vaccines and therapeutics include adeno carcinomas, mucinous carcinomas, and adenosquamous carcinomas. Adeno carcinomas are cancers that develop in mucus-secreting glands across the body. These treatments are applied in various fields such as infectious diseases, cancer treatment, and other medical applications. End users include hospitals and clinics, ambulatory surgical centers, research institutes, and others involved in medical research and healthcare delivery.

The mRNA market research report is one of a series of new reports that provides mRNA market statistics, including mRNA industry global market size, regional shares, competitors with a mRNA market share, detailed mRNA market segments, market trends and opportunities, and any further data you may need to thrive in the mRNA industry. This mRNA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

mRNA cancer vaccines and therapeutics market consists of sales of individualized cancer treatment mRNA vaccine, infectious disease treatment mRNA vaccine, and infection prevention mRNA vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.